Tau Biosensor Cell Screening for Genetic Modifiers of Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for identifying genetic modifiers of tau aggregation, which is a key factor in neurodegenerative diseases such as Alzheimer's and Parkinson's, and there is a need for effective screening techniques to understand and intervene in these diseases.
Innovation Solution
A CRISPR/Cas-based screening platform is developed to identify genetic modifiers of tau aggregation by using cells with tau repeat domains linked to reporters, introducing guide RNAs to edit or activate genes, and analyzing the formation of tau aggregates to determine genetic modifiers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CRISPR/Cas-based screening is used to identify genetic modifiers of tau aggregation, then the ability to screen for genetic modifiers is improved, but the complexity of the screening platform increases
Solution Approach 1:
The screening platform is divided into distinct functional modules: (1) cells expressing tau repeat domains with aggregation reporters, (2) CRISPR/Cas systems for gene editing, (3) guide RNA libraries for targeted gene modification, and (4) aggregation detection systems. This segmentation allows each component to be optimized independently while maintaining overall system functionality.
Solution Approach 2:
The patent uses intermediary elements to bridge different functional components: guide RNAs mediate between the CRISPR/Cas system and target genes, aggregation reporters (such as FRET pairs or fluorescent proteins) mediate between tau aggregation events and detectable signals, and conditioned medium serves as an intermediary to transfer aggregation-prone tau species between cell cultures.
2Adaptability or versatility
If guide RNAs are introduced to edit or activate genes in the screening process, then the ability to modify gene function is improved, but the time required for genome editing and expansion increases
Solution Approach 1:
The patent employs preliminary actions to accelerate the screening process: guide RNA libraries are pre-designed and validated before screening begins, cells are pre-engineered with stable expression of tau repeat domains and aggregation reporters, and CRISPR/Cas systems are pre-assembled and activated. This preliminary preparation reduces the time required during actual screening operations.
Solution Approach 2:
The screening process maintains continuous useful action through: (1) sustained expression of guide RNAs and CRISPR/Cas components throughout cell culture, (2) continuous monitoring of tau aggregation via stable reporter expression, and (3) uninterrupted propagation of genetically modified cells. This continuity eliminates idle periods and maintains productive screening throughout the experimental timeline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform effectively identifies genes that enhance or inhibit tau aggregation, providing insights into disease progression and potential therapeutic targets.
Implementation Method 1
introducing into the population of cells a library comprising a plurality of unique guide RNAs that target a plurality of genes; culturing the population of cells to allow genome editing and expansion, wherein the plurality of unique guide RNAs form complexes with the Cas protein, and the Cas protein cleaves the plurality of genes resulting in knockout of gene function
Implementation Method 2
contacting the genetically modified population of cells with a tau seeding agent to produce a seeded population of cells; culturing the seeded population of cells to allow tau aggregates to form, wherein aggregates of the first tau repeat domain and the second tau repeat domain form in a subset of the seeded population of cells
Implementation Method 3
aggregates of the first tau repeat domain and the second tau repeat domain form in a subset of the seeded population of cells to produce an aggregation-positive population of cells
Data Source
AI summary
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.